| Code | CSB-RA023984MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of utomilumab, targeting TNFRSF9 (tumor necrosis factor receptor superfamily member 9), also known as 4-1BB or CD137. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells, natural killer cells, and other immune cells. Upon binding to its ligand 4-1BBL on antigen-presenting cells, TNFRSF9 delivers critical secondary signals that promote T cell proliferation, survival, cytokine production, and enhanced cytolytic activity. This costimulatory pathway plays a central role in sustaining effective antitumor immune responses, making it an attractive target for cancer immunotherapy. Dysregulation of TNFRSF9 signaling is implicated in immune dysfunction and ineffective tumor control. Utomilumab is a fully human IgG2 agonistic monoclonal antibody that selectively binds to the extracellular domain of 4-1BB, stimulating T cell activation and expansion without the severe hepatotoxicity associated with earlier 4-1BB agonists. This biosimilar provides researchers with a valuable tool for investigating costimulatory receptor biology, studying T cell-mediated tumor immunity, and exploring combination immunotherapy strategies in preclinical cancer models. It supports research into enhancing adoptive T cell therapies and overcoming checkpoint inhibitor resistance.
There are currently no reviews for this product.